Checkpoint Therapeutics
CKPT
CKPT was delisted on the 29th of May, 2025.
2 hedge funds and large institutions have $544K invested in Checkpoint Therapeutics in 2017 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.07% more ownership
Funds ownership: 0% → 0.07% (+0.07%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OPPM
Opus Point Partners Management
New York
|
+$1.16M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$13.8K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OPPM
1
Opus Point Partners Management
New York
| $530K | +$1.16M | +11,776 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| $14K | +$13.8K | +140 | New |
|
CKPT Hedge Fund Activity: Q2 2017 in Review
2 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Checkpoint Therapeutics (CKPT) for Q2 2017, worth a combined $544K.
Buyers outnumbered sellers: 2 funds opened new CKPT positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Opus Point Partners Management, opening a new position worth an estimated $1.16M.
- 2 institutional investors held Checkpoint Therapeutics (CKPT) as of Q2 2017, up from 0 in Q1 2017.
- Funds reported $544K of Checkpoint Therapeutics stock for Q2 2017.
- 2 funds opened new Checkpoint Therapeutics positions in Q2 2017 and 0 closed out, a net change of +2 holders.
- The largest Checkpoint Therapeutics buyer in Q2 2017 was Opus Point Partners Management, an estimated $1.16M added.
Based on aggregated 13F filings for Q2 2017.